Skip to main
  1. Stocks
  2. Insight Molecular Diagnostics Inc
  3. Forecast
IMDX

IMDX Stock Forecast & Price Target

IMDX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insight Molecular Diagnostics Inc. is poised for significant long-term revenue growth as it continues to advance its innovative diagnostic testing portfolio, particularly in the fields of organ transplant monitoring and cancer. The company’s addressable market could expand by approximately 10-20% through the inclusion of reimbursement for additional testing indications related to immunosuppression and rejection, which are currently under clinical evaluation. Additionally, drivers such as clinical data presentations, favorable guideline changes, and potential acceleration in revenue growth contribute to a positive outlook for the company's financial performance.

Bears say

Insight Molecular Diagnostics Inc. is facing significant financial challenges, as evidenced by a decline in gross margin from 67.6% to 53.5%, highlighting potential cost pressures despite exceeding estimates. The company's future revenue projections appear bleak, with expectations of minimal income from the GraftAssureIQ until mid-2026, pending IVD clearance for the GraftAssureDx. Additionally, several risks could exacerbate these financial concerns, including slower physician adoption of new tests, delays in insurer coverage, and increased cash burn rates, further contributing to a negative outlook for the company’s stock.

IMDX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insight Molecular Diagnostics Inc and is not a guaranteed prediction by Public.com or investment advice.

IMDX Analyst Forecast & Price Prediction

Get the latest IMDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IMDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insight Molecular Diagnostics Inc (IMDX) Forecast

Analysts have given IMDX a Strong Buy based on their latest research and market trends.

According to 3 analysts, IMDX has a Strong Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insight Molecular Diagnostics Inc (IMDX)


IMDX Analyst Forecast & Price Prediction

Get the latest IMDX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IMDX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IMDX stock data and trends